Most men diagnosed with a prostate cancer may delay or prevent implementation aggressive treatment without this hurting their chances of survival. This is the main conclusion of a Study long duration which had been developed in the Kingdom and whose results had been published by the magazine New England Journal of Medicine.

His managers had analyzed data recorded in England between 1999 and 2009 of 82,429 men between the ages of 50 and 69 who had received prostate cancer diagnosis. Of a total sample of 1,643 enrolled in a trial to assess the effectiveness of available treatments, 545 were randomly assigned to receive active monitoring, 553 underwent prostatectomy (surgery to remove all or part of the prostate gland) and 545 received radiotherapy.

During a mean follow-up of 15 years (oscillation between 11 and 21 years) sample outcomes were compared in relation to death from prostate cancer and death from other causes, metastases and disease progression.

Full follow-up was performed in 1610 patients (98%). Risk stratification analysis showed that more than a third of men had moderate or high risk disease at the time their prostate cancer was diagnosed.

Death from prostate cancer occurred in 45 men (2.7%): 17 in the active monitoring group (3.1%), 12 (2.2%) in the prostatectomy group, and 16 (2.9%) in the receiving group. radiotherapy. Death due to other causes occurred in 356 men (21.7%), with the same rate in all three groups.

“Participants in the active group partnered with medical professionals to monitor their cancer closely and were able to significantly reduce complications such as incontinence or erectile dysfunction”

developed metastases in 51 men (9.4%) in the active follow-up group, in 26 (4.7%) in the group prostatectomy and in 27 (5.0%) within the cohort radiotherapy. That androgen deprivation therapy long-term initiation was initiated in 69 (12.7%), 40 (7.2%), and 42 (7.7%) men, respectively. Clinical improvement occurred in 141 (25.9%), 58 (10.5%), and 60 (11.0%) men, respectively.

In the active follow-up group, 133 men (24.4%) were alive without prostate cancer treatment at the end of follow-up. “No differential effects on cancer-specific mortality were observed in relation to prostate-specific antigen baseline levels, tumor stage or grade, or risk stratification score. No treatment complications were reported after 10 years of analysis,” the authors wrote.

Participants in the active group partnered with medical professionals to monitor their cancer closely and were able to significantly reduce such complications incontinence waving erectile dysfunction was associated with the most aggressive treatment, without incurring a higher risk of death than men who had prostate removal surgery or those who were treated with hormone blockers or radiotherapy.

“After 15 years of follow-up, low prostate cancer specific mortality regardless of the treatment provided”, stated those in charge of the investigation. “The choice of therapy therefore involves a trade-off between the benefits and harms associated with treatment for localized prostate cancer,” they concluded.

Because we all need health… ConSalud. es